THAP9 and esophageal squamous cell carcinoma: Together, our findings highlight a positive feedback loop of THAP9-AS1/miR-133b/SOX4 in ESCC, providing a certain theoretical basis for employing THAP9-AS1 as a potential prognostic biomarker and therapeutic target for ESCC patients.